Introduction
Rabies causes about 55,000 human deaths annually worldwide of which 31,000 human deaths occur in Asia. India has the highest rate of human rabies in the world, primarily because of stray dogs, whose number has greatly increased since a 2001 law forbade the killing of dogs. An estimated 20,000 people die every year from rabies in India, which is more than a third of the global toll. [1, 2] Rabies virus is a non-segmented negative-stranded RNA virus of the Rhabdoviridae family and induces a fatal neurological disease in humans and animals. [3] Rabies virus is unique in its mode of transmission via an animal bite and in its spread through the nervous system. After inoculation, the virus infects individual muscle cells and gains access to both sensory and motor nerve fi bre endings. The neuromuscular junction is the major site of entry into www.ijmm.org January -March 2015 under the normal light-dark rhythm, food and water supplement during the experiment. The RV CVS 10% (w/v) suspension was prepared from the infected brain specimen and inoculated in 30 Swiss albino mice, 6 groups of 5 mice each (10 −1 to 10 −6 dilution) and LD 50 was calculated by Reed and Muench method.
Pre-exposure and post-exposure treatments
Mice were divided into 3 groups of 5 mice each in both pre-exposure and post-exposure treatment. In pre-exposure treatment, mice was primed with rhuIFN α-2a (0.03ml ic/mice) 24 hour prior challenge with LD50 RV CVS. rhuIFN α-2a control mice was intracerebrally (ic) inoculated with rhuIFN α-2a (0.03 ml/mice). 50 LD 50 RV CVS (0.03 ml ic/mice) was inoculated intracerebrally and served as a virus control.
In a post-exposure treatment, 0.03 ml of 50 LD 50 RV CVS (ic route) was inoculated in Swiss albino mice 3 hours prior rhuIFN α-2a inoculation. The rhuIFN α-2a control mice was intracerebrally (ic) inoculated with rhuIFN α-2a(0.03 ml/mice). 50 LD 50 RV CVS (0.03 ml ic/mice) was inoculated intracerebrally and served as a virus control. The infected Swiss albino mice were observed for mortality upto 21 days. [12] The pre-exposure and post-exposure treatments of rhuIFN α-2a challenged with RV CVS were repeated in triplicate. All the infectious work was carried out in Biosafety level-2 cabinet.
Statistical analysis
Statistical analysis was performed using two-way analysis of variance (ANOVA) test with GraphPad Prism 5.1 software.
Results
The LD 50 titre was calculated by the Reed and Muench method. Titre of 10 4.25 LD 50 /0.03 ml of 10%w/v RV CVS stock suspension were obtained, and the challenged dose of 50 LD 50 was prepared. RV CVS challenged control mice showed characteristic rabies signs in the form of ruffl ing of hair, followed by hunch back from 3-days post infection (dpi) and toe walking, tremors and hind limb paralysis within 4-dpi of infection and subsequently succumb to death on 6 dpi [ Table 1 ]. In rhuIFN α-2a administered control mice, slight ruffl ed hair was observed from 4 dpi but no mortality was seen up to 21 days. In the pre-exposure treatment, primed rhuIFN α-2a mice challenged with 50 LD 50 RV CVS showed ruffl ed hair and hunch back on 4 dpi, followed by toe walking, tremors and hind limb paralysis from 5 dpi, which subsequently succumbed to death on 10 dpi. In the post-exposure treatment, rhuIFN α-2a was administered in Swiss albino mice after 3 hours post infection with dose of 50 LD 50 RV CVS. Signs of ruffl ed hair and hunch back were observed on 4 dpi, followed by toe walking, tremors and hind limb paralysis from 5 dpi and mortality occurred on 8 dpi. Pre-exposure treatment -
Pre-exposure treatment with dose of 50 LD 50 RV CVS. No survival was observed in mice challenged only with RV CVS on 6 days. In pre-exposure treatment the survival time was seen to be increased to 10 days; however, in post-exposure treatment the survival time was found to be 8 days. These fi ndings and two-way analysis of variance (ANOVA) proves that there is signifi cant increase in the survival time of the mice administered with rhuIFN α-2a in pre-and post-exposure studies when compared with the mice challenged only with RV CVS.
Discussion
Rabies is a lethal disease caused by neurotropic virus. When exposure to a potentially rabid animal is recognised, prompt administration of virus-neutralising antibodies together with active immunisation can prevent development of the disease. However, once clinical symptoms occurs conventional post-exposure treatment becomes ineffective and unsuccessful to prevent death. [13] Previous studies have indicated protective role of human interferon in different animal models. [9, 14] Sole administrations of interferon α or in combination with ribavirin have failed to provide survival of patients with clinical rabies encephalitis. [15] However, a group of physicians with expertise in rabies have made recommendations on therapies that could be considered for an aggressive approach. [16] The present study was undertaken to elucidate the role of rhuIFN α-2a in mice challenged with rabies virus. In the pre-exposure treatment, primed rhuIFN α-2a was inoculated in Swiss albino mice and challenged with (50 LD 50 ) of RV CVS and observed up to 21 days along with the inoculated control mice (rhuIFN α-2a and RV CVS). In the primed mice, paralysis of hind limbs and tremors were observed from the 5-day post infection (pi) and succumb to death on the 10 dpi when challenge with 50 LD 50 RV CVS, whereas the RV CVS control mice died on the 6-day post infection whereas rhuIFN α-2a control mice survived up to 21 days. In the post-exposure treatment, hind limb paralysis and tremors occurred from the 5 dpi and the mortality occurred on the 8 dpi as compared to the RV CVS control, which occurred on the 6 dpi. There was signifi cant increase in survival time of mice was observed in both pre-and post-exposure treatment with rhuIFN α-2a in comparison with RV CVS control group of mice.
A similar study conducted by Tohamy A. A et al., showed that administration of human Interferon (IFN α-2a) prior to Rabies Virus Infection increases survival in mice. The increased survival rate and reduced cytogenetic changes suggest that protection induced by interferon against rabies virus activity could be, at least partially, attributable to blockage of the replication of CVS strain of rabies virus. [12] Similar observation was reported from study involving monkeys infected with rabies virus when administered by repeated intramuscular administration of human leukocyte interferon beginning 24 h after infection. [7] Bosko Postic et al., showed simultaneous inoculation of interferon and street rabies in rabbit in opposite hind limbs decreased the mortality but interferon in vitro failed to neutralise rabies virus. [17] This is the preliminarily work done where we observed increased survival time of mice primed (pre-exposure) with rhuIFN α-2a challenged with 50 LD 50 RV CVS as compared to the virus control. Thus, the problem succinctly stated the activity of rhuIFN α-2a primed Swiss albino mice and post-exposure challenged rabies virus might show some biological/physiological activity on rabies induced infection. Both pre-exposure and post-exposure experiments showed increased survival rates as compared with the controls after known exposure to the virus. These fi ndings suggest that recombinant human interferon-α-2a might help in providing protection against rabies virus.
Further research needs to be done on the mechanism of interferon and combination therapies with anti-viral drugs that should be explored to assess its protective role in rabies treatment. 
